Piramal Pharma Solutions expands API capabilities at Digwal site

Mumbai: Piramal Pharma Limited’s Pharma Solutions business, a Contract Development and Manufacturing Organization (CDMO), has announced that the company’s site in Digwal in the state of Telangana, India, has implemented various tools to unlock Active Pharmaceutical Ingredient (API) manufacturing capacity and support client needs in drug development and on-patent projects. 

Since 2019, Piramal Pharma Solutions (PPS) has made or committed more than $30 million in capital investments, both in the infrastructure and the operational culture at the Digwal site, to improve performance, gain efficiencies, and increase capacity to meet market demands.
Now, Digwal’s R&D capabilities are being further strengthened, with approximately 20 new fume hoods coming online to support services projects. As a result, the site has recently partnered with clients on more than a dozen programs, including several which have been commercially launched and others that are under registration with the regulator. 
As part of the company’s sustainability efforts, the Digwal site is equipped with a ‘Zero Liquid Discharge’ facility to ensure all liquid waste gets adequately treated in-house and recycled back to utilities. The solvent recovery infrastructure has also been upgraded, resulting in increased distillation efficiency and a reduction in solvent consumption. In addition, close monitoring and improved governance have helped in reducing the overall freshwater consumption. 
In addition to the increased reactor capacity, the Digwal site will benefit from infrastructure upgrades that include a renovated administration block, a new canteen facility, Quality Control lab revamp, and more. The consolidation and creation of a centralized new warehouse for the storage of finished goods that features a warehouse management system (WMS) are currently underway.
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, “We are now seeing the fruits of our labor in applying Operational Excellence practices at Digwal. Coupled with the capital investment we are making, our API capabilities at the site are moving to the next level. Digwal can now take on more complex and larger-scale projects than it could in the past. It’s another example of how we continue to invest and grow to serve market demands and work with our clients to reduce the burden of disease on patients.”
The Digwal site covers more than 100 acres and employs approximately 825 FTEs. In addition to producing APIs, Digwal provides analytical services and offers anaesthetic drug product (bottling) services. The site has undergone more than twenty successful inspections by a host of regulatory agencies including FDA (US), MHRA (UK), PMDA (Japan) and ANVISA (Brazil) and has been successfully audited by numerous global customers.

Read also: 

Leave a Reply

Your email address will not be published. Required fields are marked *